Bristol-Myers Squibb stock holds above $67 as new myeloma drug gains FDA approval
Published on 08/25/2026 at 14:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb Inc. (ISIN US1078421011) stock traded at $67.28 at the New York Stock Exchange close on August 24, 2026, with a flat after-hours indication that kept the shares in the high-$60 range as investors digest fresh FY 2026 earnings guidance and a newly approved multiple myeloma therapy.
Shares consolidate around fresh 52-week highs
Per a real-time quote overview, Bristol-Myers Squibb shares finished regular US trading at $67.28 on August 24, 2026, up $0.27 or 0.40 percent on the day, with the same level quoted in post-market dealings later that afternoon. The BMY quote snapshot also highlights a 52-week trading band with a low of $40.00 and a recent high near $80.00, placing the current price much closer to the upper end of the range than to the floor.
Several institutional-investor filings published on August 25, 2026, show investors increasing exposure at these levels. One Form 13F-based summary reports that a large asset manager purchased 17,022,940 Bristol-Myers Squibb shares in the second quarter of 2026, valuing the stake at $980,862,000 and equating to ownership of 0.83 percent of the company’s equity as of the filing date. The institutional-activity overview notes that hedge funds and other institutional investors collectively hold 76.41 percent of Bristol-Myers Squibb stock outstanding, underscoring deep professional participation.
Consensus data compiled in these same filings point to a constructive sell-side view. Across a broad analyst set, Bristol-Myers Squibb currently carries an average rating characterized as Moderate Buy, with one Strong Buy, thirteen Buy, ten Hold and one Sell recommendation reflected in the tally. The consensus 12-month price objective cited in the data stands at $66.06, marginally below the late-August trading price but still broadly aligned with the current level. An analyst-consensus summary shows the same $66.06 target alongside the rating mix, giving investors a benchmark against which to frame valuation.
FY 2026 earnings guidance and valuation backdrop
A recent fundamentals overview linked to new institutional positions indicates that Bristol-Myers Squibb has published FY 2026 guidance of $6.75 to $7.00 in earnings per share, providing a clearer profitability roadmap for the current year. The FY 2026 guidance note presents this EPS range explicitly as management’s outlook.
Using the late-August 2026 share price of $67.28 and the mid-point of the EPS guidance range of $6.875, Bristol-Myers Squibb trades on a forward price-to-earnings multiple close to 9.8 times FY 2026 earnings. That multiple compares to higher valuation levels seen historically for large-cap biopharmaceutical names, reflecting that the company’s stock is priced at less than ten times the guided current-year earnings despite recent gains toward the upper half of its 52-week range.
This valuation context matters for investors assessing the balance between growth prospects and risk. On the one hand, the consensus target of $66.06 is only slightly below the latest trading price, suggesting limited upside embedded in near-term analyst models. On the other, a forward price-to-earnings ratio under 10 leaves room for multiple expansion if new products scale faster than expected or if margins improve relative to guidance. The interplay between a moderate rating, concentrated institutional ownership and a relatively modest earnings multiple helps explain why Bristol-Myers Squibb stock has held steady in the high-$60s rather than correcting sharply after its recent run.
FDA approval of CELMoD iberdomide strengthens oncology pipeline
Beyond earnings guidance and positioning, a meaningful catalyst for Bristol-Myers Squibb in August 2026 comes from US regulatory action on a novel multiple myeloma therapy. A detailed scientific report explains that following strong early clinical results, the US Food and Drug Administration has granted accelerated approval to iberdomide, branded by Bristol-Myers Squibb as Zenbexus, as the first example of what the company terms the CELMoD class of molecular glue protein degraders. The protein-degrader approval article describes iberdomide as a therapy that promotes targeted degradation of specific proteins to combat cancer cells.
In terms of treatment regimen, the FDA decision covers iberdomide in a combination including the anti-cancer monoclonal antibody daratumumab for multiple myeloma patients whose disease has relapsed and no longer responds to prior therapies. The coverage emphasizes that iberdomide, in this setting, is the first multiple myeloma drug cleared for use based on minimal residual disease metrics, indicating efficacy even when disease burden has been reduced to very low levels. This minimal residual disease data was central to the accelerated approval and sets a precedent for future regulatory evaluations of similar agents.
A separate pharmacy-focused overview lists Zenbexus (iberdomide) among six new FDA-approved drugs, noting that the FDA decision for Zenbexus was dated August 13, 2026. The pharmacy update specifies that Zenbexus is approved for use alongside daratumumab, hyaluronidase-fihj and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy, including both a proteasome inhibitor and an immunomodulatory agent. This positioning places the CELMoD therapy in the relapsed setting, where treatment options can be limited and new mechanisms of action are particularly valuable.
For Bristol-Myers Squibb, this approval adds another advanced oncology asset to its portfolio and reinforces its strategy of developing innovative immune-oncology and hematology drugs. While precise revenue projections for iberdomide are not yet detailed in the cited materials, the fact that the drug is first-in-class in the CELMoD category and supported by minimal residual disease-based evidence suggests meaningful potential in a segment of the multiple myeloma market that often faces unmet needs. The regulatory milestone, coming within weeks of the company’s FY 2026 EPS guidance communication, supports the narrative that pipeline execution remains central to Bristol-Myers Squibb’s medium-term growth story.
Analyst upgrades and technical backdrop
The valuation and pipeline context is complemented by recent changes in individual analyst views referenced in market data. A quote summary for Bristol-Myers Squibb highlights an August 5, 2026 rating action, noting that one research house raised its recommendation on the stock to Buy and set a price target of $75.00. The same data table pairs this call with the broader consensus, which still centers on a Moderate Buy stance with the $66.06 target already mentioned. The analyst action table lists the August 5, 2026 upgrade and the associated $75.00 objective, giving context for the upper bound of expectations.
On the technical side, several institutional-position reports echo the same price level for Bristol-Myers Squibb on August 25, 2026, noting that shares of NYSE:BMY or BMY stock opened at $67.30 on that date. One such technical overview states that the company’s 50-day moving average stands at $60.77 and its 200-day moving average at $59.47, indicating that the current trading price is clearly above both intermediate and longer-term trend lines.
The gap between the present price of around $67 and the moving averages near $60 reflects a period of sustained share-price strength relative to earlier in 2026. With the opening price on August 25 sitting nearly $6.53 above the 50-day moving average, Bristol-Myers Squibb stock has generated roughly double-digit percentage outperformance versus its own recent trend. For technical investors, this configuration can signal that momentum is firmly positive but also that the shares are more extended and could be sensitive to any disappointment in future earnings or pipeline updates.
Representative product: Zenbexus in multiple myeloma care
Within Bristol-Myers Squibb’s broad portfolio, Zenbexus (iberdomide) stands out as a representative product illustrating the company’s approach to targeted cancer therapies. As the first FDA-approved agent in the CELMoD class of molecular glue protein degraders, Zenbexus is designed to bind specific proteins and promote their degradation, thereby interrupting pathways that support multiple myeloma cell survival. The combination regimen approved by the FDA on August 13, 2026 incorporates Zenbexus alongside daratumumab, hyaluronidase-fihj and dexamethasone for adults who have already been treated with at least one proteasome inhibitor and one immunomodulatory agent but whose disease has relapsed.
Clinical data highlighted in scientific coverage indicate that the therapy delivered strong responses even in patients with prior exposure to multiple drug classes, leading to the accelerated approval based in part on minimal residual disease outcomes. This focus on residual disease underscores Bristol-Myers Squibb’s broader strategy of using advanced biomarkers and molecular diagnostics to refine oncology treatment and make drug approvals more directly tied to disease biology. Zenbexus therefore not only offers an additional option for relapsed multiple myeloma patients but also exemplifies the kind of high-innovation asset that can support the company’s earnings guidance and analyst confidence over the medium term.
Stock level and investor takeaway
As of the completed US session on August 24, 2026, Bristol-Myers Squibb stock closed at $67.28 on the New York Stock Exchange in US dollars, based on the cited real-time quote summary. Against FY 2026 EPS guidance of $6.75 to $7.00 and a consensus target of $66.06, the shares trade modestly above average analyst expectations but still on a forward earnings multiple under 10. Combined with the accelerated US approval of Zenbexus in mid-August 2026 and concentrated institutional ownership of 76.41 percent of outstanding shares, this leaves Bristol-Myers Squibb positioned as a large-cap biopharmaceutical name where valuation, pipeline innovation and professional investor support intersect in a relatively tight band around the high-$60s stock price.
Read more
Go deeper
More on Bristol-Myers Squibb stock
Fact box
Company: Bristol-Myers Squibb Inc.
ISIN: US1078421011
Ticker: BMY
Exchange: NYSE
Price (as of August 24, 2026, 4:00 p.m. ET): $67.28 USD
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
